Marshall Wace

Portfolio Companies 2026 for Marshall Wace: investors, rounds, and co-investor patterns from StartupFundraising.com research, updated for 2026.

Marshall Wace accounts for 23 tracked companies with verified cap-table data, 23 of which disclose round sizes totalling $5.2B. The median disclosed raise is $165M, and the largest is Ripple at $994M, ahead of Tipalti ($550M) and ConsenSys ($450M).

The names that recur most often on these portfolio cap tables are Marshall Wace (23 companies), Janus Henderson Investors (6 companies), Logos Capital (6 companies), RA Capital Management (4 companies), Redmile Group (3 companies), Invus (3 companies). By latest disclosed round, the market skews Series C (11), Series D (4), Series B (2), Series A (2).

Best funded Marshall Wace companies

  1. Ripple — $994M
  2. Tipalti — $550M (latest: Series F)
  3. ConsenSys — $450M (latest: Series D)
  4. FogPharma — $323M (latest: Series D)
  5. Metagenomi — $300M (latest: Series B)
  6. Lycia Therapeutics — $232M (latest: Series D)
  7. Ray Therapeutics — $230M (latest: Series B)
  8. Asher Bio — $215M (latest: Series C)
  9. ADARx Pharmaceuticals — $200M (latest: Series C)
  10. Turtlemint — $190M (latest: Series C)
  11. Amylyx Pharmaceuticals — $172M (latest: Series C)
  12. Third Arc Bio — $165M (latest: Series A)
  13. Century Therapeutics — $160M (latest: Series C)
  14. Elektrofi — $152M (latest: Series C)
  15. OnCusp Therapeutics — $139M

Marshall Wace North America L.P. — related firms and companies (56)

Marshall Wace North America L.P. profile · All research reports